|
End-of-day quote
Shanghai S.E.
2026-07-15
|
5-day change
|
1st Jan Change
|
|
19.25 CNY
|
-2.18%
|
 |
+10.13%
|
+9.25%
|
|
04-24 |
Dashenlin Pharma's Q1 Profit Rises 11%
|
MT
| |
04-24 |
Dashenlin Pharma's 2025 Profit Jumps 35%, Revenue Rises 4%
|
MT
| |
04-23 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2026
|
CI
| |
04-23 |
Dashenlin pharmaceutical 2025 net profit up 35.0% y/y
|
RE
| |
04-22 |
Sipai Health to Sell Stake in Pharmacy Operator to Dashenlin Pharmaceutical For RMB 51.7 Million
|
MT
| |
04-22 |
DaShenLin Pharmaceutical Group Co., Ltd. signed a equity transfer agreement to acquire Sipai Zhihe Technology Co., Ltd. from Sipai Healthcare Investment Group Co., Ltd. for CNY 79.1 million.
|
CI
| |
25-10-29 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2025
|
CI
| |
25-08-28 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2025
|
CI
| |
25-04-25 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2025
|
CI
| |
25-04-25 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2024
|
CI
| |
24-10-15 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2024
|
CI
| |
24-09-19 |
Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024.
|
CI
| |
24-09-17 |
DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback announced on May 7, 2024, has closed with 6,722,254 shares, representing 0.59% for CNY 100.72 million.
|
CI
| |
24-08-30 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024
|
CI
| |
24-07-02 |
Tranche Update on DaShenLin Pharmaceutical Group Co., Ltd.'s Equity Buyback Plan announced on May 7, 2024.
|
CI
| |
24-05-06 |
DaShenLin Pharmaceutical Group Co., Ltd. commences an Equity Buyback Plan for CNY 200 million worth of its shares, under the authorization approved on April 1, 2024.
|
CI
| |
24-04-28 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
|
CI
| |
24-04-27 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
|
CI
| |
24-03-04 |
Dashenlin Pharmaceutical Plans to Buy Back Up to 200 Million Yuan Worth of Shares
|
MT
| |
24-01-22 |
DaShenLin Pharmaceutical Group Co., Ltd. cancelled the transaction announced on January 19, 2023
|
CI
| |
23-11-27 |
Dashenlin Pharmaceutical to Boost Stake in Local Pharmacy Chain to 66% For 30 Million Yuan
|
MT
| |
23-11-24 |
DaShenLin Pharmaceutical Group Co., Ltd. agreed to acquire 15% stake in Chongqing Wanjiayan Pharmacy Chain Co., Ltd from Chongqing Wanjiayan Health Industry Group Co., Ltd. and Bai Run for CNY 30 million.
|
CI
| |
23-10-29 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
|
CI
| |
23-08-29 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
|
CI
| |
23-04-27 |
DaShenLin Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
|
CI
|
No results match your criteria Select your edition All financial news and data tailored to specific country editions | 
Choose MarketScreener 
